

Inhibitor patients
Prophylactic therapy:
none
Non-inhibitor patients
Prophylactic therapy:
FVIII formulation
ABR value = (Number of bleedings x 365.25) / Days of observation
ABR (Annualized Bleeding Rate)
(times/year)
80
70
60
50
40
30
20
10
0
28.4
0.0
-100%
20.3
0.0
-100%
36.5
12.9
-65%
56.8
8.7
-77%
77.1
59.5
-21%
8.1
0.0
-100%
31401
31601
31602
31604
31301
31603
Before ACE910 administration
After ACE910 administration

FIG. 1



Inhibitor patients
Prophylactic therapy:
none
Non-inhibitor patients
Prophylactic therapy:
FVIII formulation
ABR value= (Number of bleedings x 365.25) / Days of observation
ABR (Annualized Bleeding Rate)
(times/year)
0
10
20
30
40
50
60
70
80
18.3
0.0
-100%
38.6
4.3
-89%
18.3
0.0
-100%
18.3
0.0
-100%
14.2
0.0
-100%
10.1
0.0
-100%
32501
32601
32602
32701
32401
32502
Before ACE910 administration
After ACE910 administration

FIG. 2



ABR (Annualized Bleeding Rate)
(times/year)
0
20
40
60
80
Inhibitor patients
Non-inhibitor patients
32.5
0
20.3
0
24.3
0
10.1
0
0
0
8.1
4.2
33301
33303
33701
33201
33302
33601
Before ACE910 administration
(Prophylactic therapy:
bypassing agent)
After ACE910 administration
Before ACE910 administration
(Prophylactic therapy:
FVIII formulation)
After ACE910 administration

FIG. 3